The New York case was for ACTIVE TB disease and not latent infection which our test is being targetted at. If your test is for active disease it is easy to see if it is accurate. If your test is for latent infection there is no gold standard and as only 10% of people with latent infection convert to active disease in their lifetime it takes a very long time and a lot of testing to prove that one test is better than another - even if it is as poor as the sking test. This is why our test still has single digit market share after all this time.
CST Price at posting:
$2.63 Sentiment: None Disclosure: Not Held
